Irreversible enzyme inhibition

Why does aspirin keep working long after the drug itself has left the bloodstream?

There is a rule of thumb that everyone absorbs from taking medicines: the drug works while it is in you, and stops working as it clears. Dose interval follows half-life. It is why paracetamol is a four-hourly proposition and why a missed dose of a blood-pressure tablet shows up the same day.

Aspirin breaks the rule outright. Acetylsalicylic acid is hydrolysed so fast that its own half-life in plasma is roughly fifteen to twenty minutes. Yet a single low dose keeps platelets from clotting properly for about a week, and surgeons ask patients to stop it days in advance for exactly that reason. If the molecule is gone by lunchtime, what is still doing the work on Friday?

Start by asking what an ordinary inhibitor actually does. It binds the enzyme, sits in the way, and then — because binding is a reversible equilibrium — falls off again. At any moment the fraction of enzyme that is blocked depends on how much inhibitor is around. Lower the concentration and the equilibrium shifts back. So the effect really is tethered to the drug's presence, and the rule of thumb is not folk wisdom, it is thermodynamics.

Now notice what that argument depends on. It depends on the off step existing. What if the encounter did not end in the inhibitor leaving, but in a chemical reaction?

That is what aspirin does. It carries an acetyl group, and when it sits in the channel of cyclooxygenase it hands that group to a particular serine residue in the enzyme's active site — Ser529 in human COX-1. What is left behind is not a drug held in place by attraction; it is a covalent bond, part of the protein now. The salicylate remainder drifts off and is cleared. The acetyl group stays.

Ask yourself what happens to the equilibrium argument at that point. There is no equilibrium left. The enzyme is not blocked in proportion to how much drug is present; it has been permanently modified, and the concentration of a molecule that no longer exists in that form cannot govern anything. Whatever sets the duration of effect, it is no longer pharmacokinetics.

So what does set it? If the enzyme is destroyed for good, the only way back is a new enzyme. Duration becomes a question about protein turnover — how fast the cell makes replacements. This is the step where the reasoning becomes predictive, so it is worth pausing on: it tells you the same drug should have completely different durations in different tissues, purely as a function of how fast each one rebuilds its enzymes.

And that is exactly what is observed, in the most striking way available. Platelets have no nucleus. They are cell fragments shed from megakaryocytes in the marrow, and they carry essentially no capacity to transcribe new COX-1. A platelet whose cyclooxygenase has been acetylated is out of the thromboxane business for the rest of its life — seven to ten days — and the only recovery available to the body is the arrival of fresh platelets, roughly a tenth of the pool per day. Meanwhile the endothelial cells lining the blood vessels, which do have nuclei, resynthesise their cyclooxygenase within hours. One drug, one bond, two durations, and the difference is not chemistry at all.

The commitment is a real one in the risk sense too. A reversible inhibitor that turns out to hit the wrong target can be waited out; a covalent one cannot. That is why irreversible drugs are usually engineered to be sluggishly reactive on their own and to depend on the target's own binding pocket to bring the reactive group into position — reactivity that is merely chemical would modify everything it met.

The first misconception worth correcting is that "irreversible" means the effect is permanent. It is permanent for that molecule of enzyme, which is a different claim. In a tissue that turns its proteins over briskly, an irreversible inhibitor can have a shorter functional duration than a tight-binding reversible one. Permanence at the molecular level and duration at the clinical level are separate axes.

The second is that low-dose aspirin's platelet selectivity is not simply because platelets cannot resynthesise. Dose and route matter too: 75 to 100 mg taken by mouth acetylates platelets while they pass through the portal circulation, before much aspirin reaches the general circulation intact, so systemic cyclooxygenase is comparatively spared. The anucleate biology is what makes the effect last; the presystemic exposure is part of what makes it selective.

Third, the same architecture recurs across the pharmacopoeia once you know to look for it. Penicillin acylates the bacterial transpeptidase that cross-links cell wall peptidoglycan. Omeprazole is a prodrug that rearranges in the acid of the stomach's parietal cells and bonds to the proton pump, which is why once-daily dosing controls acid for far longer than its plasma half-life suggests. Clopidogrel's active metabolite bonds to a platelet receptor and, for the same anucleate reason, lasts the platelet's life.

One practical corollary that follows directly: ibuprofen, a reversible competitive inhibitor, can occupy the same channel and physically deny aspirin access to the serine. Taken shortly before aspirin, it can blunt the cardioprotective effect — an interaction that only makes sense once you see that aspirin needs to reach a specific residue to make its commitment.

• How covalent inhibitors are designed to be unreactive until the target's own binding pocket positions them, and how that selectivity is tested.
• Why aspirin's action on COX-2 leaves a partly functional enzyme that makes a different product, rather than shutting it down.
• How enzyme turnover rates are measured, and what they predict about dosing intervals for other irreversible drugs.

Every term the collection defines is gathered in the glossary.